Significance of this study
What is already known about this subject? ► Obesity has been recognised as a significant risk factor for hepatocellular carcinoma (HCC) development. ► Cancer cells undergo characteristic metabolic change to adapt to their local environment, socalled 'metabolic reprogramming'. ► HCC can survive even in a lipid-rich environment, leading to lipotoxicity; however, how this environment aids in the progression has not been elucidated.
What are the new findings?
► HCC adapts to this lipid-rich environment through downregulation of carnitine palmitoyltransferase 2 (CPT2), a key enzyme of fatty acid β-oxidation. ► Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation. ► Serum acylcarnitine levels are higher in patients with non-alcoholic fatty liver disease (NALFD)-related HCC than in those without HCC.
How might it impact on clinical practice in the foreseeable future?
► Upregulation of CPT2 may be therapeutic for obesity-driven and NAFLD-driven HCC. ► Acylcarnitine may be a biomarker of NAFLDrelated HCC.
AbSTrACT
Objective Metabolic reprogramming of tumour cells that allows for adaptation to their local environment is a hallmark of cancer. interestingly, obesity-driven and nonalcoholic steatohepatitis (naSH)-driven hepatocellular carcinoma (Hcc) mouse models commonly exhibit strong steatosis in tumour cells as seen in human steatohepatitic Hcc (SH-Hcc), which may reflect a characteristic metabolic alteration. Design non-tumour and Hcc tissues obtained from diethylnitrosamine-injected mice fed either a normal or a high-fat diet (HFD) were subjected to comprehensive metabolome analysis, and the significance of obesitymediated metabolic alteration in hepatocarcinogenesis was evaluated. results the extensive accumulation of acylcarnitine species was seen in Hcc tissues and in the serum of HFD-fed mice. a similar increase was found in the serum of patients with naSH-Hcc. the accumulation of acylcarnitine could be attributed to the downregulation of carnitine palmitoyltransferase 2 (cPt2), which was also seen in human SH-Hcc. cPt2 downregulation induced the suppression of fatty acid β-oxidation, which would account for the steatotic changes in Hcc. cPt2 knockdown in Hcc cells resulted in their resistance to lipotoxicity by inhibiting the Src-mediated JnK activation. additionally, oleoylcarnitine enhanced sphere formation by Hcc cells via Stat3 activation, suggesting that acylcarnitine accumulation was a surrogate marker of cPt2 downregulation and directly contributed to hepatocarcinogenesis. HFD feeding and carnitine supplementation synergistically enhanced Hcc development accompanied by acylcarnitine accumulation in vivo. Conclusion in obesity-driven and naSH-driven Hcc, metabolic reprogramming mediated by the downregulation of cPt2 enables Hcc cells to escape lipotoxicity and promotes hepatocarcinogenesis.
InTrODuCTIOn
Hepatocellular carcinoma (HCC) is the fifth most frequently diagnosed cancer and recent epidemiological studies have identified obesity as a significant risk factor in its development. [1] [2] [3] Although various mechanisms have been suggested to underlie obesity-mediated hepatocarcinogenesis, including elevated proinflammatory cytokines, the dysregulation of adipokines, oxidative and endoplasmic reticulum (ER) stress as well as altered gut microbiota, the process remains poorly understood. [4] [5] [6] [7] [8] Cancer cells undergo characteristic metabolic changes to adapt to their local environment, so-called 'metabolic reprogramming'. 9 Among the most well studied of these changes is the Warburg Hepatology effect, in which cancer cells use aerobic glycolysis rather than the normal cellular pathway of mitochondrial oxidative phosphorylation to generate the energy needed for the synthesis of nucleic acids, proteins and lipids. 10 Altered fatty acid (FA) metabolism is another property of cancer cells. 11 FAs are synthesised de novo in most cancer cells, including HCC. 11 12 In addition to their incorporation into the cell membrane, FAs serve as signalling molecules, storage compounds and an energy source. However, in the obese, the increased intake of dietary FAs together with the lipolysis of visceral adipose tissue lead to enormous exogenous FA supplies to hepatocytes via the portal vein. This lipidrich condition is a very characteristic environment for liver cancer, but how the malignant cells adapt to it and use it for their progression is unknown.
A histological variant of HCC, steatohepatitic HCC (SH-HCC), characterised by tumour cells with steatosis, pericellular fibrosis and/or inflammatory infiltrates, has been recently recognised. 13 14 Although SH-HCC occurs almost exclusively in patients with underlying steatohepatitis, with or without viral hepatitis infection, its pathogenesis has yet to be elucidated.
We recently reported a new mouse model of non-alcoholic steatohepatitis (NASH)-driven HCC, obtained by feeding a high-fat diet (HFD) to MUP-uPA mouse, which expresses urokinase plasminogen activator (uPA) under major urinary protein (MUP) promoter. 6 Importantly, HCC arising in HFD-fed MUPuPA mice is histologically similar to human SH-HCC. Furthermore, in the current study, we found that other obesity-driven and NASH-driven HCC mouse models, diethylnitrosamine (DEN) with HFD model and hepatocyte-specific PIK3CA transgenic (PIK3CA Tg) mouse model, 4 15 also showed more prominent tumour steatosis than that in non-tumour hepatocytes. We therefore hypothesised that the marked steatosis of tumour cells is representative of characteristically altered metabolism in obesity-driven HCC and thus a key phenotype linking obesity, NASH and HCC. Therefore, in the present study we carried out untargeted metabolomics profiling using mouse obesity-driven HCC tissues and found the extensive accumulation of acylcarnitine species in HCC. The significance of this finding in hepatocarcinogenesis was evaluated.
MATerIAlS AnD MeTHODS

Animal experiments
MUP-uPA and PIK3CA Tg mice were described previously. 6 15 Experimental protocols for animal models are described in the online supplementary materials and methods. All experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals.
In vitro experiments
We used DEN-induced mouse HCC cell line Dih10 for in vitro experiments. 16 Details of biochemical analyses are described in the online supplementary materials and methods.
Histology
Immunostainings were performed as described previously (see online supplementary materials and methods).
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Metabolome analyses
Metabolite extraction and metabolome analysis were conducted at Human Metabolome Technologies (Tsuruoka, Yamagata, Japan). Details are provided in the online supplementary materials and methods.
Human samples
Serum acylcarnitine levels were evaluated in serum samples collected from 250 patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD) with (n=28) and without (n=222) HCC at the University of Tokyo Hospital from November 2011 to December 2015. The recruitment criteria of liver biopsy are described in the online supplementary materials and methods. We also collected serum samples from HCV-related patients with HCC who underwent radiofrequency ablation (RFA) (n=28) during the same period. All serum samples were collected in the morning of the day of liver biopsy and/or RFA after an overnight fast.
Human SH-HCC (n=20) and conventional-HCC (n=20) samples were obtained from patients who underwent surgical treatment at the University of Tokyo Hospital from January 2008 to December 2011. The diagnosis of SH-HCC was made as described previously (see online supplementary materials and methods). 14 All patients provided informed consent.
Statistical analyses
Details of the statistical analyses are described in the online supplementary materials and methods. A two-tailed P<0.05 was considered to be statistically significant. All data analyses were performed using the 'R' statistical language (www. r-project. org).
reSulTS
Acylcarnitine species accumulate markedly in obesity-driven HCC tissues
As we previously reported, HCC tumour cells of HFD-fed MUPuPA mice exhibited marked steatosis that was more pronounced than that observed in non-tumour hepatocytes ( figure 1A ). Similar findings were obtained in other obesity-driven and NASH-driven HCC mouse models, specifically, the DEN with HFD and PIK3CA Tg models ( figure 1A) . Therefore, marked steatosis in tumour cells was a common feature among the obesity-driven and NASH-driven HCC mouse models.
To explore the characteristic metabolic changes in obesity-driven HCC, paired non-tumour (NT) and HCC tissues obtained from DEN-injected mice aged 8 months kept on a normal diet (ND) or an HFD (ND-NT, ND-HCC, HFD-NT and HFD-HCC tissues) were subjected to liquid chromatography-mass spectrometry (LC-MS)-based untargeted metabolomic profiling. The DEN model was used in this analysis because it enables comparisons of the metabolomic profile of HCC in mice fed an ND or HFD. Consistent with the previous report, 4 HCC development was markedly enhanced in HFD-fed DEN-injected mice (see online supplementary figure 1). A cluster composed of metabolites specifically accumulated in HFD-HCC tissues was identified using a hierarchical clustering analysis (figure 1B), and notably, various long-chain acylcarnitine species predominated ( figure 1C ). ND-HCC and HFD-NT tissues also showed mildly increased levels of acylcarnitine species compared with ND-NT tissues; however, in both they were much lower than that in HFD-HCC tissues ( figure 1D ). Therefore, in the following experiments we focused on the significance of acylcarnitine accumulation in obesity-driven HCC.
expression of acylcarnitine metabolism-related genes in obesity-driven HCC
Acylcarnitine accumulation in HFD-HCC was further investigated by analysing the expression of genes involved in acylcarnitine metabolism. Intracellular long-chain FAs are esterified to acyl-coenzyme A by enzymes of the long-chain acyl-coenzyme A synthase (ACSL) family and then converted to acylcarnitine via their conjugation to carnitine by carnitine palmitoyltransferase 1 (CPT1). After its mitochondrial translocation via carnitine acylcarnitine translocase (CACT), acylcarnitine is converted back to acyl-coenzyme A by CPT2 and then enters the fatty acid β-oxidation (FAO) pathway, followed by the Hepatology mitochondrial tricarboxylic acid (TCA) cycle. 18 Among these acylcarnitine metabolism-related genes, increased expression of CPT1A (a hepatic isoform of CPT1) and ACSL4 (a member of the ACSL family, the expression of which is increased in human HCC) in ND-HCC and HFD-HCC tissues 19 and decreased expression of CACT and CPT2 in HFD-HCC were detected (figure 2A). Therefore, despite the enhanced conversion of FAs to acylcarnitine in HFD-HCC tissues, the reconversion of acylcarnitine to acyl-coenzyme A was suppressed, which could account for the marked accumulation of acylcarnitine species. A similar expression pattern of acylcarnitine metabolism-related genes was observed in tumours arising in HFD-fed MUP-uPA and PIK3CA Tg mice: in particular, the downregulation of CPT2 in tumour tissues was a common finding (figure 2B). We confirmed the significantly decreased CPT2 protein expression in HFD-HCC tissues by western blot analysis (WB) and immunostaining (figure 2C, D, online supplementary figure 2A). Although CPT1A protein tended to be increased in HFD-HCC tissues, there were no statistically significant differences ( figure 2C ). Thus, we further analysed the significance of CPT2 downregulation in subsequent experiments.
A human genetic disorder, CPT2 deficiency, results in increased serum acylcarnitine levels caused by impaired FAO. 20 Similarly in this disease, CPT2 knockdown using small interfering RNA in the DEN-induced mouse HCC cell line Dih10 16 attenuated FAO with mild increase of lipid droplets after palmitic acid (PA) administration (see online supplementary figure 2B-D), and Dih10 cells with stable CPT2 knockdown significantly increased the concentration of acylcarnitine in the culture medium ( figure 2E, online supplementary figure 2E ). These observations suggested that the downregulation of CPT2 can be a causal factor for acylcarnitine accumulation in HFD-HCC.
The CPT2 expression is mainly regulated by a transcription factor, peroxisome proliferator-activated receptor α (PPARα). 21 22 All three mouse models, DEN+HFD, MUP-uPA-+HFD and PIK3CA Tg mice, exhibited significantly decreased PPARα expression in tumour tissues (figure 2F). Consistent with a previous report, 23 PPARα agonist fenofibrate upregulated CPT2 expression in Dih10 cells (figure 2G). Therefore, decreased PPARα expression might partially explain the downregulation of CPT2 in obesity-driven and NASH-driven HCC.
Analyses of serum acylcarnitine levels in human samples
Based on the observed release of acylcarnitine into the culture medium of HCC cells, total carnitine, free carnitine and acylcarnitine levels were measured in serum samples collected from DEN-injected ND-fed or HFD-fed mice and non-injected ND-fed or HFD-fed mice. As shown in figure 3A , serum acylcarnitine levels were significantly increased in HCC-bearing HFD-fed mice (figure 3A). DEN administration did not affect the CPT2 expression levels in non-tumour tissues (see online supplementary figure 2F). These findings suggested the acylcarnitine species accumulated in HCC tissues may be released into the bloodstream.
Then, we measured the serum levels of free carnitine and acylcarnitine in 250 patients with biopsy-proven NAFLD with and without HCC (table 1). While serum-free carnitine levels were similar between the two groups, serum acylcarnitine levels were significantly higher in patients with HCC (table 1, figure 3B ). Serum acylcarnitine levels increased gradually along with fibrosis progression and further increased in patients with HCC, whereas no such relationship was seen in free carnitine (see online supplementary figure 3A) . Although we also analysed the relationships between serum levels of acylcarnitine and liver steatosis, inflammation and hepatocyte ballooning, there were no significant correlations (see online supplementary figure 3B) .
To explore the possibility of serum acylcarnitine as a biomarker of HCC in patients with NAFLD, its diagnostic ability was evaluated using receiver operating characteristics (ROC) curve analysis. Area under the ROC curve (AUROC) of serum acylcarnitine level was 0.72, which was inferior to that of α-fetoprotein (AFP) (0.90) but equivalent to that of des-γ-carboxy-prothrombin (DCP) (0.62) (figure 3C). A higher serum level of acylcarnitine (>12.6 μmol/L calculated by AUROC analysis) was an independent factor associated with the presence of HCC even after adjusting for confounding factors, such as age, AFP levels and fibrosis progression ( figure 3D, online supplementary table 1, 2) . Moreover, in three patients with NAFLD in whom serum samples were sequentially collected before and at the time of HCC diagnosis, the increase in serum acylcarnitine levels paralleled HCC development (see online supplementary figure 3C) . Thus, the serum acylcarnitine level may be a potential biomarker of HCC in NAFLD.
Notably, serum acylcarnitine levels in patients with NAFLD-related HCC were significantly higher than those in patients with HCV-related HCC who had similar background data except for body mass index (BMI) (online supplementary figure 3D and table 3 ), implying that serum acylcarnitine levels are aetiology-dependent and possibly high in patients with NAFLD-related HCC.
Next, we analysed CPT2 protein expression using immunohistochemistry in surgically resected human SH-HCC samples, and the CPT2 expression was almost completely absent in some SH-HCC samples ( figure 3E ). Thus, we quantified expression levels of CPT2 in the tumour area and adjacent liver tissues in 20 SH-HCC (non-viral, n=16; HCV, n=4) using immunofluorescence staining and compared them with 20 conventional-HCC samples (HBV, n=6; HCV, n=14).
Although CPT2 expression was decreased in both conventional-HCC and SH-HCC compared with paired adjacent liver tissues, SH-HCC exhibited a greater reduction of CPT2 than conventional-HCC ( figure 3F, online supplementary figure  3E ). These findings were consistent with those in mice and supported the possibility that the increased serum acylcarnitine in patients with HCC were derived from HCC tissues.
Furthermore, to examine whether CPT2 downregulation was involved also in fibrosis-related increase of acylcarnitine, we analysed the expression levels of CPT2 mRNA in liver biopsy samples obtained from the above NAFLD cohort. However, there was no significant correlation between the serum acylcarnitine level and liver CPT2 expression irrespective of concomitant HCC (see online supplementary figure 3F), suggesting that factors other than CPT2 were involved in liver fibrosis-related increase of serum acylcarnitine in NAFLD.
Capillary electrophoresis-mass spectrometry in the analysis of the complete set of metabolites in HFD-HCC
The complete set of metabolites in mouse HCC samples was then analysed using capillary electrophoresis-mass spectrometry (CE-MS). Consistent with the decreased CPT2 expression, the amount of β-hydroxybutyrate, a by-product of FAO, was lower in HFD-HCC tissues, confirmed by direct measurements of β-hydroxybutyrate (figure 4A, online supplementary figure 4), whereas higher levels of the components of the TCA cycle were detected (figure 4B). Despite the increased amounts of the glycolytic metabolites, glucose-6-phosphate and fructose 6-phosphate, in HFD-HCC tissues, the amount of lactic acid was decreased, which is not the case in tumour cells exhibiting the Warburg effect ( figure 4B ). This result indicated that glucose was used for oxidative phosphorylation. Additionally, the decreased glutamine and increased glutamate levels measured in the HFD-HCC samples pointed to the facilitated conversion of glutamine to glutamate in a process referred to as glutaminolysis, which is another major metabolic change that maintains the TCA cycle in cancer cells ( figure 4B) . 24 Collectively, our results showed the suppression of FAO in HFD-HCC tumour cells and the alternative use of glucose and glutamine in oxidative phosphorylation. 
CPT2 downregulation enables HCC cells to adapt to lipid-rich conditions
The role of CPT2 downregulation in hepatocarcinogenesis was further investigated by analysing the effects of CPT2 knockdown on the behaviour of Dih10 cells. Cellular growth was unaffected by CPT2 knockdown, even when observed over an extended period of time using the subcutaneous xenograft model ( figure 5A, online supplementary figure 5A ). Excess amounts of saturated FAs, such as PA and stearic acid (SA), exert lipotoxicity; however, as shown in figure 5B , CPT2 knockdown significantly suppressed PA-induced and SA-induced cell death. PA induces cell death through the phosphorylation of JNK and the subsequent upregulation of Puma, 25 as we were also able to demonstrate in Dih10 cells. However, both cellular events were significantly attenuated by CPT2 knockdown (figure 5C, D). Recently, CPT2-mediated FAO was reported to induce Src activation through phosphorylation at Y419, 26 which plays a critical role in saturated FA-induced JNK activation. 27 28 In fact, PA-induced Src phosphorylation at Y419 was attenuated by CPT2 knockdown (figure 5C), and Src inhibitor suppressed PA-induced cell death (see online supplementary figure 5B). Although ER stress has also been implicated in PA-induced JNK activation, 29 induction of the ER stress marker CHOP in CPT2 knockdown cells was similar to that in control cells ( figure 5C ). These results suggested that CPT2 downregulation attenuated lipotoxicity by inhibiting the Src-mediated JNK activation. Furthermore, we established PA-resistant Dih10 cells by chronic exposure to 50% lethal concentration of PA. The PA-resistant cells acquired similar growth capacity even in the PA containing media and revealed significantly decreased expression of CPT2 
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( figure 5E, F) . These results suggest that HCC cells avoid the lipotoxicity induced by the lipid-rich cellular environment by downregulating CPT2.
Oleoylcarnitine enhances the self-renewal of HCC cells through STAT3 activation
We then investigated whether the accumulation of acylcarnitine species in HFD-HCC tissues is a surrogate marker of CPT2 downregulation or contributes directly to the promotion of HCC. Therefore, the effects of oleoylcarnitine (AC18:1) and palmitoylcarnitine (AC16:0), two abundantly accumulated acylcarnitine species in HFD-HCC, on cellular growth were investigated using Dih10 cells. As shown in figure 6A, neither AC18:1 nor AC16:0 promoted cell growth, and high concentration of AC16:0 (≥25 µM) was rather toxic to HCC cells. Since the concentration of acylcarnitine species in the tissues of obese mice is 5-10 µM, 30 in subsequent experiments AC18:1 and AC16:0 concentrations of 5 µM were used.
The effects of AC16:0 and AC18:1 on the self-renewal of HCC cells were evaluated in sphere formation assays. Remarkably, AC18:1 but not AC16:0 promoted sphere formation in Dih10 cells ( figure 6B ). In accordance with this, AC18:1 increased the expression of several stem cell markers, including Sall4, Nanog and Oct4 (figure 6C). We therefore also assessed the activation status of several oncogenic mediators, including STAT3, ERK, JNK, p38, Akt and S6, which have been reported to be involved in the HFD-mediated promotion of HCC induced by DEN, 4 in AC18:1-supplemented Dih10 cells and found significantly increased phosphorylation of STAT3 Y705 with a peak at 24 hours ( figure 6D, online supplementary   figure 6A ). The expression of STAT3 downstream target genes, Mcl-1 and Survivin, was also increased by AC18:1 supplementation (see online supplementary figure 6B). In addition, both AC18:1-induced spheroid formation and the enhanced expression of stem cell markers were abolished in cells treated with the STAT3 inhibitor WP1066 ( figure 6E, F) . This finding suggested that AC18:1 contributes directly to hepatocarcinogenesis by conferring stem cell properties to cancer cells through STAT3 activation.
HFD feeding and carnitine supplementation synergistically enhance acylcarnitine accumulation and hepatocarcinogenesis
In humans, the consumption of red meat and saturated fat is associated with an increased risk of HCC development. 31 Because red meat is a carnitine-rich food, 32 we hypothesised that saturated fat and carnitine-containing red meat synergistically accelerate hepatocarcinogenesis through acylcarnitine accumulation. We therefore supplemented DEN-injected ND-fed or HFD-fed mice with L-carnitine by adding it to their drinking water and then compared tumourigenicity in these mice versus those provided with non-supplemented drinking water ( figure 7A ). Although L-carnitine supplementation did not cause a change in tumour formation in ND-fed mice, it significantly enhanced HCC development in HFD-fed mice ( figure 7B, C) , without affecting HFD-induced body weight gain, liver steatosis or serum alanine aminotransferase levels ( figure 7D, E) . However, L-carnitine supplementation increased the amounts of acylcarnitine species, including AC 18:1, in HCC tissues ( figure 7F) . Consistent with the in vitro experiments, L-carnitine supplementation increased STAT3 phosphorylation in HCC tissues (figure 7G). Thus, HFD feeding and carnitine supplementation synergistically promoted hepatocarcinogenesis, and these results further support the tumour promoting effects of acylcarnitine.
DISCuSSIOn
The cellular adaptations caused by metabolic reprogramming in cancer cells can be clonally selected during tumourigenesis, and altered metabolism is a hallmark of cancer. 9 In comprehensive analyses of metabolomics profiling using mouse HCC samples, we identified the extensive accumulation of acylcarnitine species in obesity-driven HCC tissues. We then showed that the downregulation of CPT2 was a major cause of acylcarnitine accumulation and a common feature in mouse models of obesity-driven and NASH-driven HCC and human SH-HCC. Consistent with a recent study using liver-specific CPT2 knockout mice, 33 CPT2 downregulation resulted in FAO suppression, which would explain, at least in part, the steatotic change characteristic of hepatic cancer cells. Although FAO efficiently generates energy and is used by most cancer cells for their progression, excessive FAO as a byproduct of high intracellular fat levels leads to excessive electron flux in the electron transport chain and metabolic stress that can cause cell death. 34 In patients with NASH, the increased dietary intake of FAs and the lipolysis of visceral adipose tissue lead to an enormous exogenous supply of FAs to the liver through the portal vein. Although lipotoxic hepatocyte death is an important promoter of NASH-driven HCC, 6 HCC cells must survive in the lipid-rich environment. HCC cells in which CPT2 was knocked down acquired resistance to lipotoxicity by inhibiting the Src-mediated JNK activation, and decreased CPT2 expression was also a feature of the lipotoxicity-resistant HCC cells established by chronic exposure to PA. Consistent with our results, the genetic ablation of CPT2 in adipose tissues suppressed HFD-induced oxidative stress via 
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FAO inhibition in a recent study. 35 Therefore, the downregulation of CPT2 may enable HCC cells to adapt to the lipid-rich environment and thus avoid lipotoxicity ( figure 7H) .
Although JNK plays a tumour-promoting role in hepatocarcinogenesis, 36 37 its roles are complex and context-dependent. 38 JNK-mediated hepatocyte death promotes hepatocarcinogenesis by inducing inflammation and compensatory regeneration, 36 whereas JNK-mediated tumour cell death can suppress HCC development. 39 40 In patients with NASH, although JNK-mediated lipotoxic hepatocyte death is an important driving force of HCC, HCC cells must survive in the lipid-rich environment. Therefore, we consider that avoiding cell death by attenuating saturated FAs-induced JNK activation through CPT2 downregulation is beneficial for HCC cells in NASH.
Our results also demonstrated that acylcarnitine accumulation was not simply a surrogate marker of CPT2 downregulation but contributed directly to hepatocarcinogenesis. Recent studies highlighted the effects of acylcarnitine species on various pathophysiological conditions, such as cardiac ischaemia, insulin sensitivity and inflammation 30 32 41 ; however, little is known about the role of these compounds in carcinogenesis. In this study, AC18:1 promoted sphere formation in cultured HCC cells through the STAT3-mediated upregulation of stem cell factors. Furthermore, the extensive accumulation of acylcarnitine in response to HFD feeding and L-carnitine supplementation enhanced STAT3 activation and promoted HCC development in vivo. The IL-6/STAT3 signalling pathway was previously shown to play an important role in the transformation of liver cancer stem cells. 42 43 Thus, CPT2 downregulation enables HCC cells to escape from lipotoxicity and promotes hepatocarcinogenesis via the accumulation of acylcarnitine-mediated STAT3 activation. Although we showed the decreased PPARα expression partially explains the CPT2 downregulation in obesity-related and NASH-related HCC, the mechanism underlying the PPARα downregulation in HCC remains unknown. Therefore, further studies are needed on this issue.
Conversely, hypocarnitinaemia sometimes occurs in cachectic cirrhotic patients, 44 and L-carnitine supplementation has been reported to improve hepatic encephalopathy and muscle cramp. 45 46 A significant correlation was observed between serum and liver tissue carnitine concentrations, 47 and thus L-carnitine supplementation to compensate for carnitine deficiency is beneficial for patients with cirrhosis. However, some reports showed that patients with cirrhosis have hypercarnitinaemia. 48 Such a discrepancy might be caused by differences in the aetiology of cirrhosis, nutritional status, dietary pattern and severity of the cirrhosis. Indeed, serum carnitine levels tended to be higher in patients with NAFLD-HCC than patients with C-HCC in our study (see online supplementary figure 3C) . Importantly, to achieve a beneficial effect of carnitine supplementation, conservation of FAO pathway is considered mandatory. We showed that FAO in HFD-HCC was suppressed due to downregulation of CPT2, which was confirmed in human HCC, especially in SH-HCC, and a recent study analysing global gene expression profiling of HCC also showed significant deregulation of FAO in HCC tissues. 49 Additionally, FAO in the liver tissues of patients with NASH was reported to be impaired due to decreased activity of mitochondrial respiratory chain, 50 consistent with our results of increased serum acylcarnitine in patients with NAFLD. Although carnitine supplementation under normal FAO function is not harmful, carnitine supplementation under impaired FAO in combination with high amounts of FAs leads to extensive accumulation of acylcarnitine species, which may exert tumour-promoting effects, as shown in this study, and also toxic effects on normal tissues. 51 Indeed, L-carnitine supplementation did not promote HCC development under ND in our study. Because previous studies showing beneficial effects of carnitine were mostly based on short-term studies conducted in hepatitis virus-related cirrhosis, the long-term effect of carnitine supplementation on NASH-related cirrhosis, especially in patients with HCC, still needs to be explored.
We found significantly higher serum acylcarnitine levels in patients with NAFLD than without HCC and identified higher serum acylcarnitine as an independent factor associated with the presence of HCC even after adjusting for confounding factors. In previous metabolomic analyses of human HCC tissue samples, the levels of the acylcarnitine species AC18:1 and AC16:0 were significantly higher in HCC than in NT tissues. 12 Additionally, consistent with our results, a recent study showed high serum acylcarnitine levels in patients with HCC. 52 These findings suggest that serum acylcarnitine levels may be a potential biomarker of HCC. However, acylcarnitine species can also be released from other tissues besides the liver, and HCC may induce metabolic deregulation in other organs. Therefore, the direct relationship between serum acylcarnitine levels and HCC tissue acylcarnitine levels should be further investigated.
In contrast to red meat and saturated fat, the consumption of n-3 polyunsaturated FA-rich fish has been reported to reduce the risk of HCC. 53 Indeed, the amount of eicosapentaenoic acid (FA20:5) which can activate PPARα 54 was much lower in HFD-HCC tissues compared with ND-NT tissues (0.08-fold) in our metabolomic analysis. Therefore, fish-based diet combined with calorie restriction and exercise may be beneficial to prevent HCC in patients with obesity.
According to the WHO classification, obesity is defined as BMI ≥30 and most patients in our NAFLD cohort are classified as overweight (BMI 25.0-29.9). However, Asians have higher risk of obesity-related morbidity and mortality at lower BMI, and therefore, the Western Pacific Regional Office of WHO proposed an alternative definition of overweight (BMI 23.0-24.9) and obesity (BMI ≥25) for Asian populations. 55 According to this definition, we used the term 'obesity' in the title.
Our study had several limitations. First, we did not provide direct in vivo evidence of the tumour-promoting effect of CPT2 downregulation, and thus further studies such as knockout mouse studies are needed. Second, the sample size for our metabolomic analysis was relatively small. Analysis using a larger sample size should be conducted to clarify metabolic rearrangements in obesity-related and NASH-related HCC in more detail.
In summary, comprehensive metabolome analyses identified the extensive accumulation of acylcarnitine species following CPT2 downregulation in obesity-driven HCC tissues. CPT2 downregulation enables HCC cells to escape lipotoxicity and promotes hepatocarcinogenesis through acylcarnitine-mediated STAT3 activation. Therefore, upregulating the expression of CPT2 may be a therapeutic option for obesity-driven and NASH-driven HCC.
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